Jiangsu Cowin Biotech Co Ltd
SSE:688426
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (56.2), the stock would be worth ¥-59.24 (384% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -19.8 | ¥20.84 |
0%
|
| Industry Average | 56.2 | ¥-59.24 |
-384%
|
| Country Average | 26.4 | ¥-27.81 |
-233%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
J
|
Jiangsu Cowin Biotech Co Ltd
SSE:688426
|
2.3B CNY | -19.8 | -17 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -2 855 158.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.2B USD | 23.4 | 87.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
178.1B USD | 20.7 | 22.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
163.4B USD | 24.2 | 19.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -480.6 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.7B USD | 33.9 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.1B USD | 19.9 | 16.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 159.6 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.2B AUD | 35.5 | 29.5 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 13.7 |
| Median | 26.4 |
| 70th Percentile | 52.8 |
| Max | 2 279 450.9 |
Other Multiples
Jiangsu Cowin Biotech Co Ltd
Glance View
Jiangsu Cowin Biotech Co., Ltd. engages in the provision of molecular testing services as well as the research and development of molecular testing products. The company is headquartered in Taizhou, Jiangsu and currently employs 603 full-time employees. The company went IPO on 2022-10-25. The firm is also in the business of molecular testing services. Molecular detection products include molecular detection raw materials enzymes, nucleic acid preservation reagents, nucleic acid extraction and purification reagents and molecular diagnostic kits. The firm's products are exported to the United States, Peru, Germany and other countries and regions.
